Entasis Therapeutics Holdings Inc (ETTX) stock is higher by 15.83% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
Entasis Therapeutics Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ETTX!
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With ETTX Stock Today?
Entasis Therapeutics Holdings Inc (ETTX) stock is trading at $2.78 as of 12:40 PM on Friday, May 29, a gain of $0.07, or 2.58% from the previous closing price of $2.71. Volume today is more active than usual. So far 76,032 shares have traded compared to average volume of 26,144 shares. The stock has traded between $2.72 and $2.85 so far today.
To see InvestorsObserver's Sentiment Score for Entasis Therapeutics Holdings Inc click here.
More About Entasis Therapeutics Holdings Inc
Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its products candidate includes Zoliflodacin, ETX0282CPDP, and NBP program.
